IL159879A0 - Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine - Google Patents

Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine

Info

Publication number
IL159879A0
IL159879A0 IL15987902A IL15987902A IL159879A0 IL 159879 A0 IL159879 A0 IL 159879A0 IL 15987902 A IL15987902 A IL 15987902A IL 15987902 A IL15987902 A IL 15987902A IL 159879 A0 IL159879 A0 IL 159879A0
Authority
IL
Israel
Prior art keywords
bibn4096
migraine
treatment
combination
antimigraine drugs
Prior art date
Application number
IL15987902A
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of IL159879A0 publication Critical patent/IL159879A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL15987902A 2001-08-17 2002-08-10 Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine IL159879A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10139410A DE10139410A1 (de) 2001-08-17 2001-08-17 Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
PCT/EP2002/008993 WO2003015787A1 (en) 2001-08-17 2002-08-10 Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine

Publications (1)

Publication Number Publication Date
IL159879A0 true IL159879A0 (en) 2004-06-20

Family

ID=7695082

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15987902A IL159879A0 (en) 2001-08-17 2002-08-10 Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine

Country Status (22)

Country Link
EP (1) EP1420790B1 (de)
JP (1) JP2005503382A (de)
KR (1) KR20040027892A (de)
CN (1) CN1543347A (de)
AR (1) AR036265A1 (de)
AT (1) ATE304854T1 (de)
BR (1) BR0211970A (de)
CA (1) CA2454083A1 (de)
CO (1) CO5560577A2 (de)
DE (2) DE10139410A1 (de)
EA (1) EA200400253A1 (de)
EC (1) ECSP044979A (de)
ES (1) ES2250733T3 (de)
HR (1) HRP20040150A2 (de)
HU (1) HUP0401484A3 (de)
IL (1) IL159879A0 (de)
MX (1) MXPA04001364A (de)
NO (1) NO20041024D0 (de)
PL (1) PL365482A1 (de)
UY (1) UY27416A1 (de)
WO (1) WO2003015787A1 (de)
ZA (1) ZA200400313B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
DE10207026A1 (de) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
EP1374870A1 (de) * 2002-06-24 2004-01-02 Rita Dobmeyer Arzneimittel zur Behandlung oder Vorbeugung von Migräne
DE10314617A1 (de) * 2003-04-01 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung des Hydrochlorids der Wirkstoffbase 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin in Kombination mit Sumatriptan zur Behandlung von Migräne
DE10338407A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
DE10338402A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
US20050065094A1 (en) 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
WO2005102322A1 (de) * 2004-04-20 2005-11-03 Boehringer Ingelheim International Gmbh Verwendung eines cgrp-antagonisten in kombination mit einem serotonin-wiederaufnahme-hemmer zur behandlung von migräne
WO2005115360A2 (en) * 2004-05-11 2005-12-08 Becton, Dickinson And Company Formulations of anti-pain agents and methods of using the same
DE102004063753A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
CN102526031A (zh) * 2010-12-27 2012-07-04 湖南九典制药有限公司 一种鼻腔内使用的舒马普坦药物组合物及其制备方法
CN103385876B (zh) * 2012-05-08 2016-01-13 四川滇虹医药开发有限公司 一种夫罗曲坦的药物组合物及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59711622D1 (de) * 1996-09-10 2004-06-17 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE19937304C2 (de) * 1999-08-10 2003-08-21 Boehringer Ingelheim Pharma Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen

Also Published As

Publication number Publication date
JP2005503382A (ja) 2005-02-03
ZA200400313B (en) 2004-11-01
EA200400253A1 (ru) 2004-08-26
DE60206289T2 (de) 2006-06-08
EP1420790A1 (de) 2004-05-26
CA2454083A1 (en) 2003-02-27
NO20041024D0 (no) 2004-02-16
DE60206289D1 (de) 2006-02-02
HUP0401484A2 (hu) 2004-12-28
DE10139410A1 (de) 2003-02-27
CN1543347A (zh) 2004-11-03
MXPA04001364A (es) 2004-05-27
HRP20040150A2 (en) 2004-06-30
ES2250733T3 (es) 2006-04-16
KR20040027892A (ko) 2004-04-01
UY27416A1 (es) 2003-03-31
ECSP044979A (es) 2004-04-28
CO5560577A2 (es) 2005-09-30
HUP0401484A3 (en) 2007-03-28
ATE304854T1 (de) 2005-10-15
PL365482A1 (en) 2005-01-10
WO2003015787A1 (en) 2003-02-27
EP1420790B1 (de) 2005-09-21
AR036265A1 (es) 2004-08-25
BR0211970A (pt) 2004-09-21

Similar Documents

Publication Publication Date Title
PT1757606E (pt) Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
HUP0401023A3 (en) Use of flibanserin in the treatment of sexual disorders
EP1572890A4 (de) Slc7s als modifikatoren des p53-wegs und verwendungsverfahren
GB0109537D0 (en) Well treatment fluids and methods for the use thereof
HK1076248A1 (en) Use of rimexolone in the treatment of dry eye
GB0109414D0 (en) Well treatment fluids and methods for the use thereof
HK1072443A1 (en) Immunoconjugates for the treatment of tumours
PL372393A1 (en) Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and antimigraine agents
IL159879A0 (en) Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine
EP1575582A4 (de) Kombinationstherapie zur behandlung von akuter leukämie und myelodysplastischer syndrome
EP1581243A4 (de) Orales lactoferrin für sepsisbehandlung
ZA200210316B (en) Composition and its therapeutic use.
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
EG24959A (en) Indoles useful in the treatment of androgenreceptor related diseases.
TWI365187B (en) 7-azaindoles and the use thereof as therapeutic agents
IL160722A0 (en) Aryloxypropylamines as chemosensitizing agents in the treatment of cancer
GB0115780D0 (en) Therapeutic molecules and uses thereof
EP1450831A4 (de) Verfahren zur behandlung in situ in den lungen von säugetieren
EP1666046A4 (de) Verwendung von n-acetyl-d-aminoglycosamin bei der herstellung von arzneimitteln zur behandlung von krebs und metastasen
IL164951A0 (en) The treatment of pain with lfendropil
EP1701736A4 (de) Therapeutische mittel und ihre verwendungen
GB0106316D0 (en) Apparatus for use in the treatment of hair
GB2392839A8 (en) Use of Mycobacterium w in the treatment of tubercolosis